(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.25%.
Imunon's earnings in 2026 is -$14,329,403.On average, 7 Wall Street analysts forecast IMNN's earnings for 2026 to be -$9,822,369, with the lowest IMNN earnings forecast at -$14,128,848, and the highest IMNN earnings forecast at -$7,576,098. On average, 6 Wall Street analysts forecast IMNN's earnings for 2027 to be -$9,370,413, with the lowest IMNN earnings forecast at -$14,521,546, and the highest IMNN earnings forecast at -$5,641,775.
In 2028, IMNN is forecast to generate -$8,690,637 in earnings, with the lowest earnings forecast at -$9,026,841 and the highest earnings forecast at -$8,220,873.